Mekan Saparow

Recent publications · Crossref

5 total works indexed

1. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

   · 2018 · cited 3,970x

2. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

   · 2019 · cited 684x

3. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial

   · 2019 · cited 218x

4. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4‐year follow‐up and analysis of relative progression‐free survival from the randomized ELOQUENT‐2 trial

   · 2018 · cited 123x

5. Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study

   · 2024 · cited 113x

via Crossref · CC0